Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine adjunctive treatment for cognitive impairment in schizophrenia
IRCT20250430065539N2Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Memantine adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoints: Neuropsychiatry Unit Cognitive Assessment Tool total score, Attention and 4 more. Started Jun 2025; status: completed.
02
Drugs
memantine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20250430065539N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250430065539N2.